Author/Authors :
Ebrahimpour, Sholeh Department of Clinical Pharmacy - Tehran University of Medical Sciences, Tehran, Iran , Nosrati, Marzieh Department of Pharmacoeconomics and Pharmaceutical Management - Tehran University of Medical Sciences, Tehran, Iran , Mohammadi, Mehdi Department of Clinical Pharmacy - Alborz University of Medical Sciences, Karaj, Iran , Kamyab, Haniyeh Department of Pharmaceutical Biotechnology - Tehran University of Medical Sciences, Tehran, Iran , Sarayani, Amir Research Center for Rational Use of Drugs - Tehran University of Medical Sciences, Tehran, Iran , Mahmoodzadeh, Habibollah Cancer Institute - Imam Khomeini Hospital Complex - Tehran University of Medical Sciences, Tehran, Iran , Jahangard‐Rafsanjani, Zahra Department of Clinical Pharmacy - Tehran University of Medical Sciences, Tehran, Iran , Gholami, Kheirollah Department of Clinical Pharmacy - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
Objective: With respect to the high cost and limited availability of albumin,
its use must be restricted to indications strongly supported by solid scientific
evidence. It was anticipated that with the implementation of the National Health
Reform Plan (NHRP), the consumption of albumin would increase as the result
of decreasing patients’ out‐of‐pocket costs. This study aimed to evaluate the
efficacy of protocol implementation on the rationalization of albumin use in
surgery wards of Cancer Institute of Imam Khomeini Hospital Complex, Tehran,
Iran. Methods: This pre‐post interventional study was conducted in 32‐month
phases from January to November 2014 in an Iranian University hospital. The
first phase was before the implementation of NHRP, the second phase was after
NHRP, and the last one was after the intervention. The first and second phases
were conducted retrospectively. Data extraction was performed by a hospital
pharmacist. During the third phase, the physicians were mandated to adhere to
a local albumin protocol which had been prepared by clinical pharmacy service
and approved by drug and therapeutic committee. Appropriateness of prescriptions
regarding indication, dose, and duration based on local guideline was compared
among groups. Findings: Although hospital bed‐days of care remained consistent
among phases, albumin was prescribed for 40, 45, and 8 patients during first,
second, and third phases, respectively. This shows about 80% reduction of drug
prescriptions in the last phase. The mean duration/dose of albumin in inappropriate
indications reduced significantly from 11.3 ± 8.2 days/24.7 ± 21.2 vials in the
second phase to 2.6 ± 1.7 days/5.6 ± 3.5 vials in the third phase, respectively
(P = 0.001 and P = 0.003). Conclusion: Interactive collaboration through guideline
implementation seems effective in rationalizing the use of high‐cost medications
such as albumin.
Keywords :
Albumin , cost , drug utilization evaluation , practice guideline